Our Technology
EptivA Therapeutics has developed the first precision medicine approach to pain to create more effective treatments and increase clinical success.
Current R&D still relies on non-translatable preclinical models with a focus on a single node of data, the target receptor
Our innovative new approach
We have created a Personalized Analgesics® bioinformatic approach which creates 1000’s nodes of data via novel human-focused network biology linked to our proprietary Pain Landscape®
EptivA Therapeutics Ltd has a published patent for research and methods relating to Personalized Analgesics® research.
Serial No. WO2023058000A1
Priority date: 08/10/2021
​
​
VALIDATION: case study
Our platform technology has been validated with a wide range of mechanisms - from estbalished medicines to novel research targets as well as through a research collaboration with Bayer Pharmaceuticals
Targets examined through our methodology include:
-
CGRP (clinically established target)
-
TRPV3 (pre-clinically established target)
-
GPR18 (orphan GPCR)
-
SV2a (pre-clinical false positive)
-
FAAH (pre-clinical false positive)
In this case study, applying our technology on CGRP established multiple disease associations
-
It identified the strongest disease association to migraine, for which CGRP medicines exist, with associations to various other novel pain conditions